Merus Scores Its First FDA Approval For Lung Cancer Drug
Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
Promising Potential of Merus’s Petosemtamab in HNSCC: A Buy Recommendation
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Merus Positioned for Growth Amid Promising Clinical Data and Resilience to Market Fluctuations
Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...
Citigroup Issues Positive Forecast for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
The Pharma Letter2d
Positive early data on Merus’ petosemtamab
Netherlands-based clinical-stage biotech Merus on Saturday announced interim clinical data as of a July 5, 2024 data cutoff ...
Merus (NASDAQ:MRUS) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
pharmaphorum6d
Merus grabs first-in-class US approval for NRG1 cancer drug
Bizengri (zenocutuzumab) targets the NRG1 gene and has been cleared by the FDA to treat advanced pancreatic adenocarcinoma ...
The Pharma Letter6d
A first for Merus’ Bizengri with FDA nod
The US Food and Drug Administration (FDA) yesterday granted accelerated approval to Bizengri (zenocutuzumab-zbco; Zeno) from ...
AOL6d
Merus Scores Its First FDA Approval For Lung Cancer Drug
On Wednesday, the FDA approved Merus N.V.’s (NASDAQ:MRUS) Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell ...
Morningstar4d
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
M.D., Ph.D., Chief Medical Officer of Merus. “Further, the monotherapy durability of petosemtamab thus far compares favorably to current standard of care, which we believe is another positive ...
Benzinga.com6d
Merus Scores Its First FDA Approval For Lung Cancer Drug
FDA approves Merus' Bizengri for advanced pancreatic adenocarcinoma and NSCLC with NRG1 fusion, showing ORRs of 40% and 33%. Bizengri approval based on eNRGy trial data; DOR in pancreatic ...